NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has scheduled its second quarter 2025 financial results announcement for August 12, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can join via webcast or telephone, with the webcast being archived on NeuroPace's investor relations website for at least 90 days.
NeuroPace (NASDAQ: NPCE), un'azienda di dispositivi medici specializzata nel trattamento dell'epilessia, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 12 agosto 2025 dopo la chiusura del mercato.
La societ脿 terr脿 una conference call alle 13:30 PT / 16:30 ET dello stesso giorno. Gli investitori potranno partecipare tramite webcast o telefono; il webcast sar脿 archiviato sul sito delle relazioni con gli investitori di NeuroPace per almeno 90 giorni.
NeuroPace (NASDAQ: NPCE), una empresa de dispositivos m茅dicos especializada en el tratamiento de la epilepsia, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 12 de agosto de 2025 despu茅s del cierre del mercado.
La compa帽铆a realizar谩 una llamada conferencia a las 1:30 PM PT / 4:30 PM ET ese mismo d铆a. Los inversores podr谩n unirse v铆a webcast o tel茅fono, y el webcast estar谩 disponible en el sitio web de relaciones con inversores de NeuroPace durante al menos 90 d铆as.
NeuroPace (NASDAQ: NPCE)電� 臧勳 旃橂毳� 鞝勲鞙茧 頃橂姅 鞚橂旮瓣赴 須岇偓搿�, 2025雲� 2攵勱赴 鞛 鞁れ爜 氚滍憸毳� 2025雲� 8鞗� 12鞚� 鞛� 毵堦皭 頉勳棎 鞓堨爼頃橁碃 鞛堨姷雼堧嫟.
須岇偓電� 臧欖潃 雮� 鞓ろ泟 1:30 PT / 鞓ろ泟 4:30 ET鞐� 旎嵓霟办姢 旖滌潉 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� 鞗轨簮鞀ろ姼雮� 鞝勴檾搿� 彀胳棳頃� 靾� 鞛堨溂氅�, 鞗轨簮鞀ろ姼電� NeuroPace 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐� 斓滌唽 90鞚缄皠 鞎勳勾鞚措笇霅╇媹雼�.
NeuroPace (NASDAQ: NPCE), une entreprise de dispositifs m茅dicaux sp茅cialis茅e dans le traitement de l'茅pilepsie, a pr茅vu l'annonce de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le 12 ao没t 2025 apr猫s la cl么ture du march茅.
La soci茅t茅 tiendra une conf茅rence t茅l茅phonique 脿 13h30 PT / 16h30 ET le m锚me jour. Les investisseurs pourront y assister via webcast ou t茅l茅phone, le webcast 茅tant archiv茅 sur le site des relations investisseurs de NeuroPace pendant au moins 90 jours.
NeuroPace (NASDAQ: NPCE), ein Medizintechnikunternehmen, das sich auf die Behandlung von Epilepsie spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r den 12. August 2025 nach B枚rsenschluss geplant.
Das Unternehmen wird am selben Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten. Investoren k枚nnen per Webcast oder Telefon teilnehmen; der Webcast wird f眉r mindestens 90 Tage auf der Investor-Relations-Website von NeuroPace archiviert.
- None.
- None.
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2025 after market close on Tuesday, August 12, 2025. The company鈥檚 management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Investors interested in listening to the conference call may do so by accessing a live webcast of the event at . Individuals interested in participating in the call via telephone may access the call by dialing +1-877-407-3982 and referencing Conference ID 13754370. The webcast will be archived on the company鈥檚 investor relations website at and will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.聽
Investor Contact:
Scott Schaper
Head of Investor Relations
FAQ
When will NeuroPace (NPCE) report Q2 2025 earnings?
How can I listen to NeuroPace's Q2 2025 earnings call?
What time is NeuroPace's Q2 2025 earnings call?
How long will NeuroPace's Q2 2025 earnings webcast be available?
